Polyrizon shares drop after FDA meeting for PL-14.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: SeekingAlpha
Polyrizon Ltd. shares fell by 21.76%, crossing down the 5-day SMA amid a challenging market environment.
The company recently completed a successful pre-submission meeting with the FDA regarding its PL-14 Allergy Blocker, which is set to enter clinical trials in 2026. This meeting clarified key regulatory requirements, positioning Polyrizon for future submissions.
Despite the positive regulatory progress, the stock's decline reflects broader market weakness, with the Nasdaq-100 and S&P 500 both down, impacting investor sentiment.
Analyst Views on PLRZ
About PLRZ
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
